O

Ovid Therapeutics

Develops therapies for rare neurological disorders

Overview

Develops medicines for rare neurological disorders such as Angelman syndrome, Fragile X syndrome, and CDKL5 deficiency disorder. The company translates discoveries from human genetics and cellular biology into therapies through research and development, then advances them through clinical trials and regulatory approvals to reach patients. Its products work by targeting specific genetic or cellular pathways that underlie these conditions, aiming to improve neurological function and quality of life. Compared with others in biotech, it differentiates itself by a science-driven, patient-focused approach that closely collaborates with rare disease communities and pursues partnerships and licensing to bring therapies to market. The goal is to deliver safe, effective treatments for patients who have few or no options today and to improve outcomes through validated, life-changing medicines.

Work here?Claim your company

About Ovid Therapeutics

Simplify's Rating
Not yet rated

We're working on gathering enough insights on this company, check back soon!

Industries

BiotechnologyHealthcare

Company Size

11-50

Company Stage

IPO

Headquarters

New York City, United States

Founded

2014

Get referred to Ovid Therapeutics

See people who can refer or advise you

Funding

Total Funding

$529.9M

Above

Industry Average

Funded Over

9 Rounds

Private Placement VC funding comparison data is currently unavailable. We're working to provide this information soon!
Private Placement VC Funding Comparison Coming Soon

Benefits

  • Hybrid Work Options

Growth & Insights

6 month growth

9%

1 year growth

25%

2 year growth

7%

Recently Posted Jobs

Sign up to get curated job recommendations

Ovid Therapeutics is Hiring for 3 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs